Lähteenvuo, Markku http://orcid.org/0000-0002-7244-145X
Tiihonen, Jari http://orcid.org/0000-0002-0400-6798
Funding for this research was provided by:
Suomen Lääketieteen Säätiö
Sosiaali- ja Terveysministeriö
University of Eastern Finland (UEF) including Kuopio University Hospital
Article History
Accepted: 7 June 2021
First Online: 1 July 2021
Declarations
:
: Open access funding provided by University of Eastern Finland (UEF) including Kuopio University Hospital. This work was supported by the Finnish Ministry of Social Affairs and Health through the developmental fund for Niuvanniemi Hospital. Markku Lähteenvuo has also received personal research funding from The Finnish Medical Foundation for the period of this work.
: Jari Tiihonen reports personal fees from the Finnish Medicines Agency (Fimea), European Medicines Agency, Eli Lilly, Janssen-Cilag, Lundbeck, and Otsuka; is a member of an advisory board for Lundbeck; has participated in research projects funded by grants from Janssen-Cilag and Eli Lilly to his employing institution, and has received grants from the Stanley Foundation and Sigrid Jusélius Foundation. Markku Lähteenvuo is a board member of Genomi Solutions Ltd. and Nursie Health Ltd., and has received honoraria from Sunovion Ltd., Orion Pharma Ltd. Otsuka Ltd., Lundbeck Ltd., and Janssen-Cilag.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: This review was requested and instructed by the journal. ML conceptualized and drafted the manuscript. JT planned the work and provided critical revision for important intellectual content.